Log in

OTCMKTS:ATTBFAbattis Bioceuticals Stock Price, Forecast & News

$0.0083
0.00 (0.00 %)
(As of 05/22/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.01
Now: $0.01
$0.01
50-Day Range
$0.01
MA: $0.01
$0.01
52-Week Range
$0.00
Now: $0.01
$0.08
Volume605,812 shs
Average Volume607,603 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Abattis Bioceuticals Corp., a biotechnology company, researches, develops, licenses, and markets ingredients and formulas for use in the biopharma, nutraceutical, cosmetic, and animal nutrition markets in Canada. It is also involved in the possession of cannabis and related active ingredients, as well as the production of extracts; and marketing services. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.38 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ATTBF
CUSIPN/A
CIKN/A
Phone604-674-8232

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive ATTBF News and Ratings via Email

Sign-up to receive the latest news and ratings for ATTBF and its competitors with MarketBeat's FREE daily newsletter.

Abattis Bioceuticals (OTCMKTS:ATTBF) Frequently Asked Questions

How has Abattis Bioceuticals' stock been impacted by COVID-19 (Coronavirus)?

Abattis Bioceuticals' stock was trading at $0.0077 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ATTBF shares have increased by 7.8% and is now trading at $0.0083. View which stocks have been most impacted by Coronavirus.

Has Abattis Bioceuticals been receiving favorable news coverage?

News articles about ATTBF stock have trended extremely negative recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Abattis Bioceuticals earned a media sentiment score of -4.6 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutAbattis Bioceuticals.

Who are some of Abattis Bioceuticals' key competitors?

Who are Abattis Bioceuticals' key executives?

Abattis Bioceuticals' management team includes the following people:
  • Mr. Robert Abenante, Pres, CEO & Director
  • Mr. Douglas J. Sorocco LLB, Advisor (Age 48)
  • Mr. Guy P. Dancosse, Advisor (Age 75)
  • Mr. Francesco Paolini, CFO & Director
  • Mr. Patrick Mitchell, Chief Operating Officer

What is Abattis Bioceuticals' stock symbol?

Abattis Bioceuticals trades on the OTCMKTS under the ticker symbol "ATTBF."

How do I buy shares of Abattis Bioceuticals?

Shares of ATTBF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Abattis Bioceuticals' stock price today?

One share of ATTBF stock can currently be purchased for approximately $0.01.

What is Abattis Bioceuticals' official website?

The official website for Abattis Bioceuticals is www.abattis.com.

How can I contact Abattis Bioceuticals?

The company can be reached via phone at 604-674-8232.

This page was last updated on 5/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.